Castleman Disease

Definition

Castleman disease is a rare group of lymph-node disorders discussed in the current source through David Fajgenbaum’s severe relapsing systemic illness and treatment research.

Current Synthesis

The episode supplies a patient-research narrative rather than a complete clinical account. Fajgenbaum describes enlarged lymph nodes, profound fatigue, abdominal pain, fluid accumulation, organ failure, transfusion and dialysis needs, and multiple near-fatal relapses before and after diagnosis by lymph-node biopsy. Chemotherapy and an experimental drug produced only temporary control in his account.

Faced with another relapse, he stored longitudinal blood samples, analyzed immune-cell and serum-protein signals, and examined lymph-node tissue. He reports identifying mTOR activation and asking his physician to prescribe sirolimus, an mTOR inhibitor used for transplant rejection. His subsequent long remission is an important hypothesis-generating case and the origin story for a wider patient-research network, but it is not by itself a universal Castleman treatment rule.

Key Claims

• Castleman disease can involve lymph-node pathology and severe systemic inflammatory illness.
• Diagnosis in the reported case followed biopsy after lymphoma and autoimmune disease were considered.
• Longitudinal patient samples helped generate a mechanism-linked treatment hypothesis.
• Fajgenbaum reports durable remission after physician-supervised sirolimus use.
• A single response cannot establish subtype-specific efficacy, dose, safety, or generalizability.
• Patient organizations can connect samples, experts, research priorities, and treatment learning.

Evidence

• Illness and diagnosis - Using Existing Drugs in New Ways to Treat & Cure Diseases of Brain & Body | Dr. David Fajgenbaum recounts Fajgenbaum’s symptoms, organ failure, biopsy, diagnosis, and relapsing course.
• Mechanistic hypothesis - Using Existing Drugs in New Ways to Treat & Cure Diseases of Brain & Body | Dr. David Fajgenbaum describes longitudinal sampling and reported mTOR activation.
• Treatment response - Using Existing Drugs in New Ways to Treat & Cure Diseases of Brain & Body | Dr. David Fajgenbaum attributes more than eleven years of remission at recording to ongoing sirolimus treatment.
• Network effect - Using Existing Drugs in New Ways to Treat & Cure Diseases of Brain & Body | Dr. David Fajgenbaum connects the individual case to research organization and use of sirolimus in additional patients.

Counterevidence & Qualifications

The source does not specify the complete Castleman classification, diagnostic criteria, differential workup, laboratory values, pathology, treatment sequence, dose, adverse effects, or primary-study evidence. Fajgenbaum’s account should not be generalized across subtypes or patients. Sirolimus is an immunosuppressive prescription drug requiring specialist judgment and monitoring; response attribution is not independently established by this summary.

What Changed

• Established a bounded disease page centered on the reported relapsing systemic case and mTOR-sirolimus hypothesis.
• Preserved the distinction between a durable individual response and general treatment evidence.

Related Concepts

• David Fajgenbaum - patient-researcher whose case supplies the current evidence.
• Drug Repurposing - method used to identify sirolimus as a candidate treatment.
• Patient-Led Rare-Disease Infrastructure / 患者主导的罕见病基础设施 - organizational response to fragmented expertise and small populations.
• Self-Experimentation - adjacent hypothesis-generation route with single-person limits.
• Medical Risk Management - clinical boundary for diagnosis, immunosuppression, and monitoring.